CN1201723C - 皮肤与组织护理和/或治疗制剂及其应用 - Google Patents
皮肤与组织护理和/或治疗制剂及其应用 Download PDFInfo
- Publication number
- CN1201723C CN1201723C CNB998098426A CN99809842A CN1201723C CN 1201723 C CN1201723 C CN 1201723C CN B998098426 A CNB998098426 A CN B998098426A CN 99809842 A CN99809842 A CN 99809842A CN 1201723 C CN1201723 C CN 1201723C
- Authority
- CN
- China
- Prior art keywords
- preparation
- salt
- peroxide
- skin
- zinc oxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims abstract description 44
- 150000001413 amino acids Chemical class 0.000 claims abstract description 37
- 239000011787 zinc oxide Substances 0.000 claims abstract description 22
- -1 alkaline earth metal salts Chemical class 0.000 claims abstract description 21
- 150000002978 peroxides Chemical class 0.000 claims abstract description 19
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 16
- 235000010755 mineral Nutrition 0.000 claims abstract description 16
- 229940088594 vitamin Drugs 0.000 claims abstract description 14
- 229930003231 vitamin Natural products 0.000 claims abstract description 14
- 235000013343 vitamin Nutrition 0.000 claims abstract description 14
- 239000011782 vitamin Substances 0.000 claims abstract description 14
- 239000011707 mineral Substances 0.000 claims abstract description 13
- 239000011573 trace mineral Substances 0.000 claims abstract description 11
- 235000013619 trace mineral Nutrition 0.000 claims abstract description 11
- 239000011230 binding agent Substances 0.000 claims abstract description 10
- 239000002502 liposome Substances 0.000 claims abstract description 10
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims abstract description 9
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims abstract description 9
- 230000000843 anti-fungal effect Effects 0.000 claims abstract description 6
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 6
- 229940121375 antifungal agent Drugs 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims description 100
- 229940024606 amino acid Drugs 0.000 claims description 36
- 235000001014 amino acid Nutrition 0.000 claims description 36
- 239000003921 oil Substances 0.000 claims description 19
- 239000000463 material Substances 0.000 claims description 18
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 13
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 9
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 9
- 229910052783 alkali metal Inorganic materials 0.000 claims description 9
- 150000001447 alkali salts Chemical class 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 239000004475 Arginine Substances 0.000 claims description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 8
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 8
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 8
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 8
- 239000001654 beetroot red Substances 0.000 claims description 8
- 239000004474 valine Substances 0.000 claims description 8
- 230000000295 complement effect Effects 0.000 claims description 7
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 7
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 claims description 6
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 claims description 6
- SPAGIJMPHSUYSE-UHFFFAOYSA-N Magnesium peroxide Chemical compound [Mg+2].[O-][O-] SPAGIJMPHSUYSE-UHFFFAOYSA-N 0.000 claims description 6
- 235000012734 epicatechin Nutrition 0.000 claims description 6
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 claims description 6
- DLINORNFHVEIFE-UHFFFAOYSA-N hydrogen peroxide;zinc Chemical group [Zn].OO DLINORNFHVEIFE-UHFFFAOYSA-N 0.000 claims description 6
- 239000000080 wetting agent Substances 0.000 claims description 6
- 229940105296 zinc peroxide Drugs 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 5
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 5
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
- 239000004472 Lysine Substances 0.000 claims description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 5
- 229960003067 cystine Drugs 0.000 claims description 5
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 5
- 239000011777 magnesium Substances 0.000 claims description 5
- 229910052749 magnesium Inorganic materials 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- PFUVRDFDKPNGAV-UHFFFAOYSA-N sodium peroxide Chemical compound [Na+].[Na+].[O-][O-] PFUVRDFDKPNGAV-UHFFFAOYSA-N 0.000 claims description 5
- 239000011701 zinc Substances 0.000 claims description 5
- 229910052725 zinc Inorganic materials 0.000 claims description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 4
- 201000009053 Neurodermatitis Diseases 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 4
- 206010040954 Skin wrinkling Diseases 0.000 claims description 4
- 239000012752 auxiliary agent Substances 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- LHJQIRIGXXHNLA-UHFFFAOYSA-N calcium peroxide Chemical compound [Ca+2].[O-][O-] LHJQIRIGXXHNLA-UHFFFAOYSA-N 0.000 claims description 4
- 229910052802 copper Inorganic materials 0.000 claims description 4
- 239000010949 copper Substances 0.000 claims description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 4
- 235000018417 cysteine Nutrition 0.000 claims description 4
- 239000011737 fluorine Substances 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 229960000310 isoleucine Drugs 0.000 claims description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 4
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 4
- 239000011591 potassium Substances 0.000 claims description 4
- 229910052700 potassium Inorganic materials 0.000 claims description 4
- XXQBEVHPUKOQEO-UHFFFAOYSA-N potassium superoxide Chemical compound [K+].[K+].[O-][O-] XXQBEVHPUKOQEO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052710 silicon Inorganic materials 0.000 claims description 4
- 239000010703 silicon Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 4
- 230000037303 wrinkles Effects 0.000 claims description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- 206010007882 Cellulitis Diseases 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 3
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 3
- 206010042496 Sunburn Diseases 0.000 claims description 3
- 206010000496 acne Diseases 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 239000000460 chlorine Substances 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 239000002537 cosmetic Substances 0.000 claims description 3
- 239000011630 iodine Substances 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000011574 phosphorus Substances 0.000 claims description 3
- 229910052698 phosphorus Inorganic materials 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 201000008261 skin carcinoma Diseases 0.000 claims description 3
- 239000004343 Calcium peroxide Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 235000019402 calcium peroxide Nutrition 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 17
- 239000000126 substance Substances 0.000 abstract description 5
- 239000007767 bonding agent Substances 0.000 abstract description 4
- 239000000341 volatile oil Substances 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 229910052784 alkaline earth metal Inorganic materials 0.000 abstract 1
- 229960003237 betaine Drugs 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 22
- 235000019198 oils Nutrition 0.000 description 17
- 241000196324 Embryophyta Species 0.000 description 16
- 230000004060 metabolic process Effects 0.000 description 11
- 230000004089 microcirculation Effects 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 244000269722 Thea sinensis Species 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- 230000004071 biological effect Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 239000003925 fat Substances 0.000 description 7
- 235000019197 fats Nutrition 0.000 description 7
- 229960003136 leucine Drugs 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 229960003121 arginine Drugs 0.000 description 6
- 229930003935 flavonoid Natural products 0.000 description 6
- 235000017173 flavonoids Nutrition 0.000 description 6
- 150000002215 flavonoids Chemical class 0.000 description 6
- 235000009569 green tea Nutrition 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 229960004295 valine Drugs 0.000 description 6
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 5
- 239000011648 beta-carotene Substances 0.000 description 5
- 235000013734 beta-carotene Nutrition 0.000 description 5
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 5
- 229960002747 betacarotene Drugs 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000013583 drug formulation Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000000474 nursing effect Effects 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 241000628997 Flos Species 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 229940093797 bioflavonoids Drugs 0.000 description 4
- 239000001110 calcium chloride Substances 0.000 description 4
- 229910001628 calcium chloride Inorganic materials 0.000 description 4
- 239000001506 calcium phosphate Substances 0.000 description 4
- 229910000389 calcium phosphate Inorganic materials 0.000 description 4
- 235000011010 calcium phosphates Nutrition 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 230000002962 histologic effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000001814 pectin Substances 0.000 description 4
- 235000010987 pectin Nutrition 0.000 description 4
- 229920001277 pectin Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000001488 sodium phosphate Substances 0.000 description 4
- 229910000162 sodium phosphate Inorganic materials 0.000 description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 4
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 4
- 235000019156 vitamin B Nutrition 0.000 description 4
- 239000011720 vitamin B Substances 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- 239000000230 xanthan gum Substances 0.000 description 4
- 229920001285 xanthan gum Polymers 0.000 description 4
- 229940082509 xanthan gum Drugs 0.000 description 4
- 235000010493 xanthan gum Nutrition 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 102000004310 Ion Channels Human genes 0.000 description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 3
- 229930003270 Vitamin B Natural products 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 235000011399 aloe vera Nutrition 0.000 description 3
- 230000019522 cellular metabolic process Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 229960002885 histidine Drugs 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 229960003646 lysine Drugs 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 239000002366 mineral element Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 235000019155 vitamin A Nutrition 0.000 description 3
- 239000011719 vitamin A Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 229940045997 vitamin a Drugs 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- 241001116389 Aloe Species 0.000 description 2
- 240000003538 Chamaemelum nobile Species 0.000 description 2
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 2
- 206010054949 Metaplasia Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000006468 Thea sinensis Nutrition 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 150000001747 carotenoids Chemical class 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229960002433 cysteine Drugs 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 235000018927 edible plant Nutrition 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 2
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 2
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 2
- 229960002733 gamolenic acid Drugs 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229960002449 glycine Drugs 0.000 description 2
- 150000002333 glycines Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 230000015689 metaplastic ossification Effects 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 229960001153 serine Drugs 0.000 description 2
- 230000037204 skin physiology Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 229960004441 tyrosine Drugs 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- KXGFMDJXCMQABM-UHFFFAOYSA-N 2-methoxy-6-methylphenol Chemical compound [CH]OC1=CC=CC([CH])=C1O KXGFMDJXCMQABM-UHFFFAOYSA-N 0.000 description 1
- SODWJACROGQSMM-UHFFFAOYSA-N 5,6,7,8-tetrahydronaphthalen-1-amine Chemical compound C1CCCC2=C1C=CC=C2N SODWJACROGQSMM-UHFFFAOYSA-N 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 241001465180 Botrytis Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000011302 Brassica oleracea Nutrition 0.000 description 1
- 241000722685 Callitris rhomboidea Species 0.000 description 1
- 240000007436 Cananga odorata Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 244000166124 Eucalyptus globulus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 240000008669 Hedera helix Species 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 241000331120 Krameria cistoidea Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- KSMRODHGGIIXDV-YFKPBYRVSA-N N-acetyl-L-glutamine Chemical compound CC(=O)N[C@H](C(O)=O)CCC(N)=O KSMRODHGGIIXDV-YFKPBYRVSA-N 0.000 description 1
- CAHKINHBCWCHCF-JTQLQIEISA-N N-acetyl-L-tyrosine Chemical compound CC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CAHKINHBCWCHCF-JTQLQIEISA-N 0.000 description 1
- DZTHIGRZJZPRDV-UHFFFAOYSA-N N-acetyltryptophan Chemical compound C1=CC=C2C(CC(NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-UHFFFAOYSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 240000001890 Ribes hudsonianum Species 0.000 description 1
- 235000016954 Ribes hudsonianum Nutrition 0.000 description 1
- 235000001466 Ribes nigrum Nutrition 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 244000295490 Salvia japonica Species 0.000 description 1
- 235000005794 Salvia japonica Nutrition 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229940118377 Vitamin antagonist Drugs 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000021324 borage oil Nutrition 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 239000010238 camphora Substances 0.000 description 1
- 229940025250 camphora Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 210000002583 cell-derived microparticle Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 150000001887 cortisones Chemical class 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229960003645 econazole nitrate Drugs 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000001632 homeopathic effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000002655 kraft paper Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 239000011133 lead Substances 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 229960001682 n-acetyltyrosine Drugs 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- NCYVXEGFNDZQCU-UHFFFAOYSA-N nikethamide Chemical compound CCN(CC)C(=O)C1=CC=CN=C1 NCYVXEGFNDZQCU-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 229940033080 omega-6 fatty acid Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229920001568 phenolic resin Polymers 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 235000008729 phenylalanine Nutrition 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000037039 plant physiology Effects 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000008171 pumpkin seed oil Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000010677 tea tree oil Substances 0.000 description 1
- 229940111630 tea tree oil Drugs 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 229960001296 zinc oxide Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/40—Peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/22—Peroxides; Oxygen; Ozone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/75—Anti-irritant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Radiation-Therapy Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及皮肤与组织护理和/或治疗制剂。确切地说,本发明涉及用于组织损害表现及后果的护理、保护和预防和用于皮肤与组织的治疗的制剂,其中所述制剂包含至少一种选自碱金属盐和碱土金属盐和其它矿物质的盐,其特征在于它含有至少一种氨基酸和氧化锌和/或无机过氧化物。任选地,本发明制剂可以另外含有收敛剂、粘结与粘合剂、湿润剂、精油、tego-甜菜碱、辅助性植物物质(例如表儿茶素)、不饱和脂肪酸、脂质体、维生素、微量元素和抗真菌和/或抗微生物组分。
Description
本发明涉及皮肤与组织护理和/或治疗制剂。本发明尤其涉及用于组织损害表现及后果的护理、保护和预防和用于皮肤与组织的治疗的制剂,其中所述制剂包含至少一种选自碱金属盐、碱土金属盐和其它矿物质的盐,其特征在于它含有至少一种氨基酸和氧化锌和/或无机过氧化物,优选为过氧化镁或过氧化钠。任选地,本发明制剂可以另外含有收敛剂、粘结与粘合剂、湿润剂、精油、tego(含苯酚-甲醛树脂牛皮纸)-甜菜碱、辅助性植物物质(例如表儿荼素)、不饱和脂肪酸、脂质体、维生素、微量元素和抗真菌和/或抗微生物组分。
天然养分是细胞和机体的健康所必需的。它们能够供养和再生皮肤,以及促进细胞的代谢和供氧。养分供应的广泛意义在皮肤护理、美容和皮肤医学领域中也变得越来越重要。激素水平改变、素质、不均衡与不正当的饮食和不健康的习惯(尤其是吸烟和缺乏锻炼)会引起典型的皮肤表现,例如组织改变、组织变形和细胞代谢障碍。有目的的养分供应可协调代谢,因此带来自然的细胞生理平衡。
众所周知,维生素、矿物质和微量元素是皮肤养分供应所不可缺少的。由氨基酸构成的蛋白质是细胞和内源性活性物质(例如酶和某些激素)的重要组成部分。对健康和功效来说,多不饱和脂肪酸、辅助性植物物质(例如类黄酮和表儿茶素)和脂质体一般变得越来越重要。维生素、矿物质和微量元素、多不饱和脂肪酸和生物活性植物物质(例如类黄酮)是必需的代谢调节剂和皮肤健康的保护性养分。
维生素是必需的营养成分,对异养生物的正常功能来说,必须得到供应,或多或少地带有强制性,相当于必需品,因为它们只能从外部来源或在环境(millieu)因素(例如肠内菌丛)的影响下获得。它们的特殊的生物催化作用是以代替进行代谢消耗的酶的活性基团为基础的。从科学角度来说,已知例如B族维生素在中间代谢中起到辅酶的作用,维生素C、E和β-胡萝卜素主要起抗氧化剂的作用。由不充分的供应或吸收、肠内菌丛紊乱或代谢紊乱、抗维生素作用或消耗增加所导致的缺乏会引起维生素缺少和维生素缺乏。
此外,矿物质和微量元素是必需的代谢调节剂。锌、镁和B族维生素是高性能的元素,因为它们可激活酶,因此可进行碳水化合物、脂肪和蛋白质物质的代谢。硅对皮肤的稳定性和养护具有有利作用。此外,科学上无可争辩的是,锌对免疫系统和皮肤代谢具有必需的功能。
多不饱和脂肪酸含有亚油酸和α-与γ-亚麻酸,它们在代谢中是生物活性调节剂(例如二十碳化合物和前列腺素)的重要起始物质,确保代谢中的健康平衡。目前,二十碳化合物和前列腺素也称为组织激素,它们对健康的稳定作用受到科学家们的广泛关注。多不饱和脂肪酸对健康皮肤功能以及炎症过程的有利影响是已知的。此外,还已知ω-3-脂肪酸(二十碳五烯酸、α-亚麻酸)和ω-6-脂肪酸(亚油酸,γ-亚麻酸)类型的多不饱和脂肪酸对神经性皮炎和牛皮癣以及负荷诱发的再生过程具有有利作用。所谓的辅助性植物物质(在专业科学中也称为生物活性植物物质)对健康的重要性现在也受到关注。生物类黄酮有效地支持维生素C关于耐受力、血管壁和结缔组织的作用,也算在这些天然植物物质中。此外,还已知生物类黄酮具有抗氧化剂的性质,因此它们协同补充维生素C、E和β-胡萝卜素的作用。
关于生物合成方面,氨基酸分为必需的、半必需的和非必需的氨基酸。除了作为蛋白质的组成部分以外,氨基酸还是生物学上有效化合物的前体。氨基酸例如参见L.Stryer,生物化学(Biochemie),Spektrum Akademischer Verlag,Oxford,1994和吕姆普化学百科全书(Roempp Lexikon Chemie),editor J.Falbe,M.Regitz,关键词“氨基酸”,Thieme Verlag,1996以及引用在这里的参考文献。
脂质体是被单层或多层磷脂双膜所包围的粒子,在内部含水相中可以加载亲水性药物分子。利用它们作为药物载体,可以实现活性物质的选择性局部富集和活性物质的延迟释放。
商业上可得到大量用于治疗和预防霉菌的、微生物的、病理的和其它组织损害表现及后果、组织改变、组织变形和细胞代谢障碍以及对人组织造成的其它形式损害的制剂。例如各种治疗皮肤和结缔组织问题的治疗手段。不过,很多这些制剂的成功是不可靠的,因为这些制剂不能到达受损害的细胞和/或作用于受损害的细胞。此外,很多商业上可得到的产品没有采取科学家们所发现的活性机理,在该机理中以天然方式为细胞补充矿物质,并刺激代谢以重新建立细胞的天然内部压力,使细胞体积正常化,并持续地转移和分泌脂质和废物。
DE-OS-19622708描述了用于局部和肠胃外体内用药的植物生物学制剂,用于预防、护理和治疗各种病理后果和其它内源性与外源性后果、改变和疾病,以及用于维持、恢复和重新建立动物和人器官和软组织中的内环境稳定,其特征在于它含有下列组分:
(a)一种或多种含有离子的组分和矿物盐,
(b)一种或多种收敛组分、一种或多种粘结剂、湿润剂和一种或多种精油,和
(c)可选的一种或多种植物提取物、胶凝剂、酸结合剂、透明质酸酶或其它适当组分,含量在0.01与20%之间。该制剂任选地含有金盏花、金缕梅或其它顺势医疗组分、氨基酸、酶、维生素、电解质、染剂、蜡、乳化剂、淀粉、凡士林、石蜡、油、酸、脂肪、植物混合物与提取物、尿素、硫酸盐化合物等。该专利申请既没有公开氨基酸的例子,也没有在实施例中使用氨基酸。
本发明的目的是提供皮肤与组织的护理和/或治疗制剂,该制剂的突出之处在于快速的作用、优异的耐受性、广泛的应用范围和特别强的深度作用。特别是该制剂应可用于组织损害表现及后果的护理、保护、预防和用于皮肤与组织的治疗。根据本发明的制剂应采取这样的研究成果,离子通过离子通道扩散进入细胞内空间,并改善细胞内的微循环。
通过提供包含下列组分的组合物以达到本发明的目的:
(a)至少一种选自碱金属盐与碱土金属盐和其它矿物质的盐,
其特征在于它含有
(b)至少一种氨基酸,和
(c)氧化锌和/或无机过氧化物。
优选地,组合物的组分(c)采用氧化锌、过氧化镁或过氧化钠。
在优选的实施方式中,本发明制剂可以在每种情况下彼此独立地另外包含至少一种收敛剂、湿润剂、精油、tego-甜菜碱、辅助性植物物质(例如类黄酮和表儿茶素)、不饱和脂肪酸、脂质体、维生素、微量元素和抗真菌与抗微生物组分。此外,还可以包含常用的载体和助剂以及粘结与粘合剂和常用的溶剂。在优选的实施方式中,本发明制剂是通过直接在作用部位上用药加以局部使用的。
本发明制剂采取这样的新的研究成果,离子通过离子通道扩散进入细胞内空间。据此,矿物盐离子穿透皮肤上层,深入皮下组织、结缔组织和脂肪细胞的细胞内部。本发明制剂尤其采用这样的原理,利用由制剂活性物质的组合所产生的高渗透压,在细胞内部与细胞外部之间进行离子交换。不过在该过程中,氨基酸扮演了重要角色,它们帮助离子更有效地克服细胞膜的天然屏障以到达细胞内部的实际作用部位。
即使细胞关于离子活性的功能受到限制,本发明组合物仍然是特别有效的。特别是当离子活性受到限制时,氨基酸充当额外的物质载体,该物质的渗入是细胞内活性所必须的,目的是在此发挥功能。已经发现,与盐的使用相比,氨基酸与氧化锌和/或无机过氧化物的组合改善细胞内微循环。这种改善作用是可以观察和生物测量到的。如果仅使用盐,那么细胞内微循环的增加在约1.5小时后突然降回至原始值。当使用包含氨基酸与氧化锌和/或无机过氧化物的组合的组合物时,与盐的使用相比,微循环的改善作用更强、更连续、持续时间更长,并缓慢地接近原始值。这使物质更好地渗入细胞,更好地在细胞内分布,由此增加了协同效应。
此外,与单独的盐形成对照,盐与氨基酸的组合对皮肤生理机能具有更积极的作用。特别是影响皮肤的保湿因子、pH值和sebometry。当盐与氨基酸结合使用时,盐比没有氨基酸时更有效地渗入细胞,因为氨基酸在一方面是细胞膜的钥匙,另一方面支持和提高离子通道的活化作用。
碱金属盐和碱土金属盐和其它矿物质是代谢所必需的调节剂。本发明中,可以使用所有已知的碱金属盐和碱土金属盐和其它矿物质,它们也可以是微量元素。可以用在本发明中的碱金属盐和碱土金属盐和矿物质的优选代表是钠、钾、镁、钙、硅、锌、锰、铜、铁、氟、氯、溴、碘和磷。优选的微量元素是偶然的微量元素,例如银、金、铝、钡、铋、镉、铬、镍、铅、锡、钛和钒,和必需的微量元素,例如铬、钴、铜、氟、铁、碘、锰、钼和硒,它们例如以酶、色蛋白和激素成分的形式存在。本发明制剂中碱金属盐和碱土金属盐和其它矿物质的量优选为10至90重量百分率,更优选为20至85重量百分率,具体在可局部用药的制剂中,优选为10至30重量百分率,更优选为10至25重量百分率,以制剂中全部组分的总和计,因所需的渗透效果而异。碱金属盐和碱土金属盐和其它矿物质以常用的盐化合物或有机化合物的形式加入。例如,钠、钾和镁优选以它们的氯化物盐的形式加入,钠和钙优选以磷酸盐的形式加入。
任选地用在本发明中的收敛剂包含为此常用的化合物。优选用作收敛剂的是单宁、金缕梅、大黄、拉坦尼(Ratanhia)和鼠尾草。本发明中收敛剂的量优选为0至30重量百分率,更优选为1至25重量百分率,以制剂中全部组分的总和计。收敛剂优选以纯的形式加入。
本发明中,可以任选地使用常用的湿润剂。优选的湿润剂是甘油、芦荟、胶原、脱酰胺胶原、胶原水解物、弹性蛋白水解物、玻璃粘液溶液(Hyalomuccoloesung)、纤维刺激素、PN 73、Q 10、水、翠叶芦荟胶、茶提取物、常春藤提取物(Hedera Helix)、母菊(春黄菊)油和丁二醇。本发明制剂中湿润剂的量优选为0至70重量百分率,更优选为5至50重量百分率,以制剂中全部组分的总和计。
此外,本发明制剂可以任选地包含常用的精油。优选的精油是春黄菊、熏衣草、迷迭香、樟脑、山松、薄荷、茶树和桉树的油。本发明制剂中精油的量优选为0至70重量百分率,更优选为3至50重量百分率,以制剂中全部组分的总和计。精油优选以纯的形式或提取物的形式或冷榨和热榨油的形式加入。
本发明制剂可以含有所有已知的氨基酸和氨基酸衍生物。优选的氨基酸和氨基酸衍生物是丙氨酸、苯丙氨酸、半胱氨酸、胱氨酸、脯氨酸、酪氨酸、丝氨酸、组氨酸、甘氨酸、亮氨酸、异亮氨酸、缬氨酸、色氨酸、精氨酸、赖氨酸、天冬酰胺和谷氨酰胺。特别地使用胱氨酸、半胱氨酸、脯氨酸、丝氨酸、组氨酸、枸杞碱、亮氨酸、异亮氨酸、缬氨酸、酪氨酸、精氨酸、赖氨酸、天冬酰胺和谷氨酰胺。尤其优选的是胱氨酸、组氨酸、甘氨酸、亮氨酸、缬氨酸、精氨酸、赖氨酸和谷氨酰胺。可以使用氨基酸的D-型、DL-型和L-型,其中L-型是优选的。氨基酸衍生物的例子是N-乙酰化形式,例如N-乙酰-L-谷氨酰胺、N-乙酰-L-酪氨酸和N-乙酰-DL-色氨酸。氨基酸和氨基酸衍生物可以单独或以混合物形式使用。本发明制剂中氨基酸和氨基酸衍生物的量优选为0.1至40重量百分率,更优选为0.2至30重量百分率,最优选为0.2至15重量百分率,以制剂中全部组分的总和计。氨基酸和它们的衍生物优选以纯的形式加入。
本发明制剂进而以氧化锌和/或无机过氧化物的存在为特征。无机过氧化物优选采用过氧化锌、过氧化钠、过氧化钾、过氧化钙或过氧化镁。氧化锌和/或无机过氧化物例如可用于调节渗透压。令人惊奇地是,与单用过氧化镁相比,氨基酸与氧化锌和/或无机过氧化物的组合具有特别好的作用。本发明制剂中氧化锌和无机过氧化物的总量优选为0.5至50重量百分率,更优选为1.5至40重量百分率,以制剂中全部组分的总和计。如果局部用药的话,无机过氧化物的量应当优选为不大于10重量百分率,更优选为不大于6重量百分率,最优选为不大于3重量百分率,如果内部用药的话,则优选为不大于20重量百分率,更优选为不大于15重量百分率。氧化锌和无机过氧化物优选以纯的形式加入。
任选地,本发明制剂中可以另外存在tego-甜菜碱。本发明制剂中tego-甜菜碱的量优选为0至25重量百分率,更优选为1至20重量百分率,最优选为5至10重量百分率,以制剂中全部组分的总和计。
任选地,本发明制剂可以含有所有已知的生物活性植物物质,也叫辅助性植物物质。用在本发明中的辅助性植物物质尤其包含类胡萝卜素、植物甾醇、皂甙、多元酚、类黄酮、萜烯、植物雌激素、硫化物、肌醇六磷酸和食纤维质。上述生物活性植物物质中,用在本发明中的尤其是多元酚、类黄酮和生物类黄酮。天然来源的生物类黄酮是本发明制剂尤其优选的。生物活性植物物质在优选的制剂实施方式中的含量优选为0至75重量百分率,更优选为2至50重量百分率,以制剂中全部组分的总和计。优选的生物类黄酮天然来源是蔬菜,例如豆类、胡萝卜、番茄、花椰菜和辣椒、玉米、芝麻、柑橘果实、绿茶和红茶、圣约翰草、葡萄等。生物活性植物物质优选以提取物的形式加入。
任选地,本发明制剂中可以另外使用所有已知的不饱和脂肪酸。优选地使用包括在植物油和动物油(例如鱼油)中的不饱和脂肪酸。植物来源的多不饱和脂肪酸是重要的代谢调节剂(二十碳化合物和前列腺素)所必需的前体。本发明制剂中不饱和脂肪酸的量优选为0至70重量百分率,更优选为2至45重量百分率,以制剂中全部组分的总和计。不饱和脂肪酸优选的纯植物来源的例子是晚樱油、亚麻油、橄榄油、麦胚油、豆油、向日葵油、琉璃苣油、南瓜子油和红醋栗种子的油。不饱和脂肪酸优选以冷榨油的形式加入。
任选地,本发明制剂进而可以另外含有常用的脂质体、卵磷脂和lipodermine。脂质体是重要的,因为它们控制维生素A和维生素E的释放。藉此方式这些维生素可以长时间加以利用。本发明制剂中脂质体、卵磷脂或lipodermine的量优选为0至30重量百分率,更优选为2至20重量百分率,以制剂中全部组分的总和计。
任选地,本发明制剂可以另外包含表儿荼素,优选是从绿茶中获得的。表儿茶素可以延缓细胞的老化。此外,它们是重要的辅助物质,能够支持维生素等微量养分的作用。制剂中表儿茶素的量优选为0至60重量百分率,更优选为2至30重量百分率,以制剂中全部组分的总和计。表儿茶素优选以纯的形式或提取物的形式加入。
任选地,本发明制剂可以另外包含所有已知的典型维生素和维生素原。特别优选用在制剂中的是维生素A、B族维生素、维生素C、D、E和β-胡萝卜素。本发明制剂中维生素的量优选为0至75重量百分率,更优选为5至50重量百分率,以制剂中全部组分的总和计。维生素以提取物的天然形式和合成形式(例如B-维生素)加入,由此维生素的作用上的差异与该事实无关。
任选地,本发明制剂可以另外包含抗真菌和抗微生物组分。可以向本发明制剂中加入抗生素、抑菌剂、皮质甾类、可的松类、硝酸益康唑、地塞米松、羟基苯甲酸盐等。制剂中抗真菌和抗微生物组分的量优选为0至60重量百分率,最优选为2至30重量百分率,以制剂中全部组分的总和计。
任选地,本发明制剂可以包含所有已知的助剂、添加剂与载体物质、常用的粘结与粘合剂和溶剂。优选的例子是乳脂、未氢化的、部分氢化的或氢化的豆脂、豆油、核桃脂、甘油、明胶、果胶、卵磷脂、β-胡萝卜素、山梨醇溶液、氧化铁、二氧化钛、染剂、脂肪、蜡、乳化剂(例如Pentafarm Ltd.,CH的IRICALMIN)、聚硅氧烷、聚乙烯、聚山梨酮(polysorbitone)、(甲基)丙烯酰基化合物、滑石、dragantum、黄原胶、淀粉、凡士林、葡萄糖、糖精、石蜡、酸、防腐剂和芳香剂。可使用果胶作为粘结剂和粘合剂。上述物质和试剂以常用量使用,例如,果胶最多为10重量百分率,以制剂中全部组分的总和计。
本发明制剂可以按照本领域技术人员公知的方式加以制备,例如将活性成分与适当的、无毒的、惰性的、药学上可接受的固体或液体载体物质和可选的常用添加剂、助剂和溶剂一起制成盖仑给药剂型。制造软膏和霜剂等盖仑给药剂型的方法例如描述于H.Sucker,B.Fuchs,P.Speiser,“制药技术”(“PharmazeutischeTechnologie”)第2版(1991),Georg Thieme Verlag Stuttgart;R.Voigt,“制药技术教科书”(“Lehrbuch der pharmazeutischenTechnologie”),Thieme Verlag,1976。对本发明制剂来说,所有已知的用药剂型都是可能的。优选的用药剂型是霜剂、软膏、糊剂、乳剂、洗剂、流体、溶液、凝胶、粉末、喷雾剂、明胶剂、泡沫等。内部用药剂型例如胶囊剂、片剂、包衣片、口服液和注射液,例如皮下注射。作为用药剂型,缓释形式也是可能的。
原则上,所有已知的用药方式对本发明制剂来说都是可能的。最优选的是局部用药,例如将相应的用药剂型施用于皮肤,例如涂抹、摩搓、轻轻地摩擦、喷雾、轻拍等。用药也可以是软膏绷带或皮下注射的形式。本发明制剂每天可以施用一次或多次,可以历经较短和较长时间。不过,每日剂量和每天的用药频率因各发明制剂的配方而异。
根据配方的不同,本发明制剂适合作为营养补充剂、化妆品或药物组合物,优选为局部化妆品或局部药物组合物,施用于哺乳动物的皮肤与组织上,例如用于组织损害表现与后果的护理、保护和预防,用于皮肤与组织的治疗。根据配方的不同,它们在优选的实施方式中特别可用于所有的皮肤刺激(例如皮肤生理机能紊乱、晒伤)、蜂窝织炎、皱纹、痤疮、疱疹、牛皮癣、神经性皮炎、臭氧损害、灼伤、腐蚀性灼伤、细胞代谢紊乱和其它有组织液、脂肪与其它细胞产物及细胞分解代谢产物蓄积的改变,例如增厚、水肿、血肿,此外例如可用于痔、风湿病、关节病和皮肤癌。该制剂也可以用于粘膜,例如胃和肠道粘膜。
本发明通过实施例加以进一步阐述。
实施例1
按常用方法制备根据本发明的制剂,具有下列组分:
氧化锌 8wt%
过氧化钠 3wt%
磷酸钠 10wt%
磷酸钙 6wt%
氯化钙 5wt%
精氨酸 7wt%
亮氨酸 8wt%
天冬酰胺 5.5wt%
缬氨酸 2wt%
金缕梅 1wt%
单宁 3wt%
果胶 1wt%
tego-甜菜碱 2wt%
维生素A 1wt%
维生素E 1.5wt%
β-胡萝卜素 0.5wt%
胶原 1.5wt%
芦荟 2wt%
橄榄油 2wt%
类胡萝卜素 2wt%
明胶 1wt%
脂质体 2wt%
纯净水,加至 100wt%
将上例组合物施用于被试者的一条腿。对另一条腿施用对照物(安慰剂;对照腿)。检查结果总结如下:
作为上述发明配方的急性反应,发现微循环增加。约50分钟后,之后观察到微循环显著改善,约100分钟后达到最大增加。约120分钟之后观察到显著有效期。在对照腿上,观察到微循环没有变化。作为由本发明配方的用药所导致的进一步反应,可以观察到治疗腿上脂肪层减少了,而对照腿上没有改变。通过这些检查显示,本发明制剂能够显著改善微循环,减少脂肪层。
实施例2
量(wt%)
天冬酰胺 0.30
亮氨酸 0.20
缬氨酸 0.30
精氨酸 0.20
过氧化锌 0.50
磷酸钙 4.50
磷酸钠 3.50
透明氧化锌 2.00
氯化钙 4.00
硫酸镁 3.00
蒸馏水 62.90
金缕梅 2.50
tego-甜菜碱 2.00
山梨醇 6.00
迷迭香油 0.30
薄荷醇 0.30
绿茶粉 1.00
常春藤/问荆/藻/绿茶 5.00
黄原胶 1.50
上述发明制剂按常用方法制备。
首先,测量被试者特定皮肤区域上的微循环。然后,在该皮肤区域轻轻地摩擦实施例2配方。然后立即测量微循环,然后每半小时测量一次,共计4小时。以通量单位测量微循环。将测量结果对时间作图。将包含盐和过氧化镁的商业上可得到的产品象本发明制剂一样施用于另一块皮肤区域,与之相比,当使用包含某些氨基酸与氧化锌和过氧化锌的组合的本发明配方时,观察到微循环上升较早,维持较高水平,历经较长时间,平缓恢复至原始值要晚得多。在相应的测量点上,与商业产品相比的改善作用在7与15%之间。结果显示,本发明配方与商业产品相比,具有提高了的系统和协同效果。
实施例3
按常用方法制备根据本发明的制剂,具有下列组分:
量(wt%)
蒸馏水 71.15
磷酸钙 1.50
亮氨酸 0.20
缬氨酸 0.30
精氨酸 0.20
天冬酰胺 0.30
过氧化锌 0.25
磷酸钠 1.50
透明氧化锌 3.00
Karion FP液 4.00
Neo Dragold液 0.30
氯化钙 1.50
硫酸镁 2.50
绿茶粉 2.00
金盏花 3.00
金缕梅 2.50
圣约翰草 3.00
芳香剂1677 0.30
澳大利亚茶树油 1.00
黄原胶 1.50
实施例4
按常用方法制备根据本发明的制剂,具有下列组分:
量(wt%)
蒸馏水 66.70
透明氧化锌 2.00
磷酸钠 3.00
天冬酰胺 0.05
磷酸钙 3.50
氯化钙 3.50
亮氨酸 0.20
硫酸镁 3.00
过氧化锌 0.30
tego-甜菜碱 2.00
金缕梅 2.50
山梨醇 5.00
YLANG-YLANG油II 0.10
莲花芳香剂-精油混合物 0.10
薄荷醇 0.05
绿茶粉 0.50
IRICALMIN 3.00
GLYCODERM 3.00
黄原胶 1.50
在进一步应用中,观察到该配方对皮肤的老化、弹性、水分、皱纹形成和绷紧性方面都具有显著积极的效果。
Claims (19)
1.一种包含下列组分的制剂用于制备药物的应用:
(a)10至90重量%的至少一种选自碱金属盐、碱土金属盐和其它矿物质的盐,
(b)0.1至40重量%的至少一种氨基酸,以制剂中的所有组分的总和计,
(c)氧化锌和/或无机过氧化物,
所述药物用于治疗皮肤晒伤、蜂窝织炎、皱纹、痤疮、疱疹、神经性皮炎、臭氧损害、灼伤、腐蚀性灼伤和皮肤癌。
2.用于局部施用的制剂,它包含下列组分:
(a)10至90重量%的至少一种选自碱金属盐、碱土金属盐和其它矿物质的盐,
(b)0.1至40重量%的至少一种氨基酸,
(c)氧化锌和/或无机过氧化物和
(d)大于0至小于或等于75重量%的至少一种辅助性植物物质,以制剂中的所有组分的总和计。
3.根据权利要求2的制剂,其特征在于,它还包含:
(e)大于0至小于或等于70重量%的至少一种植物来源的多不饱和脂肪酸。
4.根据权利要求2的制剂,其特征在于它另外包含至少一种不饱和脂肪酸。
5.根据权利要求2至4任意一项的制剂,其特征在于它另外包含tego-甜菜碱和/或至少一种表儿茶素和/或至少一种微量元素。
6.根据权利要求2至4任意一项的制剂,其特征在于它另外包含至少一种脂质体和/或至少一种维生素。
7.根据权利要求2至4任意一项的制剂,其特征在于它另外包含至少一种收敛剂和/或至少一种湿润剂和/或至少一种精油。
8.根据权利要求6的制剂,其特征在于它另外包含至少一种收敛剂和/或至少一种湿润剂和/或至少一种精油。
9.根据权利要求2至4任意一项的制剂,其特征在于它另外包含抗真菌和/或抗微生物组分。
10.根据权利要求2至4任意一项的制剂,其特征在于它另外包含至少一种选自载体物质、助剂、添加剂、粘结剂、粘合剂和溶剂的组分。
11.根据权利要求2至4任意一项的制剂,包含下列组分:
总量为0.5至50wt%的氧化锌和无机过氧化物,以制剂中全部组分的总和计。
12.根据权利要求6的制剂,包含下列组分:
总量为0.5至50wt%的氧化锌和无机过氧化物,以制剂中全部组分的总和计。
13.根据权利要求2至4任意一项的制剂,包含下列组分:
(a)至少一种盐,选自钠、钾、镁、钙、硅、锌、锰、铜和铁与氟、氯、溴、碘和磷之间形成的盐,
(b)至少一种氨基酸,选自胱氨酸、半胱氨酸、脯氨酸、丝氨酸、组氨酸、甘氨酸、亮氨酸、异亮氨酸、缬氨酸、酪氨酸、精氨酸、赖氨酸、天冬酰胺和谷氨酰胺,和
(c)氧化锌和/或无机过氧化物。
14.根据权利要求6的制剂,包含下列组分:
(a)至少一种盐,选自钠、钾、镁、钙、硅、锌、锰、铜和铁与氟、氯、溴、碘和磷之间形成的盐,
(b)至少一种氨基酸,选自胱氨酸、半胱氨酸、脯氨酸、丝氨酸、组氨酸、甘氨酸、亮氨酸、异亮氨酸、缬氨酸、酪氨酸、精氨酸、赖氨酸、天冬酰胺和谷氨酰胺,和
(c)氧化锌和/或无机过氧化物。
15.根据权利要求2至4任意一项的制剂,其特征在于该无机过氧化物是过氧化锌、过氧化钠、过氧化钾、过氧化钙或过氧化镁。
16.根据权利要求3至15任意一项所定义的制剂的用途,用于制备局部施用的制剂。
17.根据权利要求2至15任意一项所定义的制剂的用途,用作化妆品。
18.根据权利要求2至15任意一项所定义的制剂的用途,用于制备药物组合物。
19.根据权利要求18的用途,所述药物组合物用于治疗皮肤晒伤、蜂窝织炎、皱纹、痤疮、疱疹、神经性皮炎、臭氧损害、灼伤、腐蚀性灼伤和皮肤癌。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19831798.0 | 1998-07-15 | ||
DE19831798A DE19831798A1 (de) | 1998-07-15 | 1998-07-15 | Mittel zur Pflege und/oder Behandlung von Haut und Gewebe |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1313753A CN1313753A (zh) | 2001-09-19 |
CN1201723C true CN1201723C (zh) | 2005-05-18 |
Family
ID=7874155
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB998098426A Expired - Fee Related CN1201723C (zh) | 1998-07-15 | 1999-07-15 | 皮肤与组织护理和/或治疗制剂及其应用 |
Country Status (18)
Country | Link |
---|---|
EP (2) | EP1639991A3 (zh) |
JP (1) | JP3917370B2 (zh) |
KR (1) | KR100542606B1 (zh) |
CN (1) | CN1201723C (zh) |
AT (1) | ATE308968T1 (zh) |
AU (1) | AU761947B2 (zh) |
BR (1) | BR9912821A (zh) |
CA (1) | CA2337772C (zh) |
DE (3) | DE19831798A1 (zh) |
DK (1) | DK1096918T3 (zh) |
ES (1) | ES2252976T3 (zh) |
HK (1) | HK1037958A1 (zh) |
HU (1) | HUP0103236A2 (zh) |
IL (1) | IL140889A0 (zh) |
NO (1) | NO20010220L (zh) |
PL (1) | PL345689A1 (zh) |
WO (1) | WO2000003689A2 (zh) |
ZA (1) | ZA200101244B (zh) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7629384B2 (en) | 1997-09-17 | 2009-12-08 | Strategic Science & Technologies, Llc | Topical delivery of L-arginine to cause beneficial effects |
US7914814B2 (en) | 1997-09-17 | 2011-03-29 | Strategic Science & Technologies, Llc | Topical delivery of arginine of cause beneficial effects |
DE20005402U1 (de) | 2000-03-22 | 2000-07-20 | Schilling Johann Georg | Mittel zur äußerlichen Behandlung von Hautrötungen und Schuppenflechten |
JP4532706B2 (ja) * | 2000-09-08 | 2010-08-25 | 花王株式会社 | 化粧料 |
DE10109798A1 (de) * | 2001-03-01 | 2002-09-12 | Aventis Pharma Gmbh | Gesundheitsfördernde Zusammensetzung von Verbindungen |
DE10133202A1 (de) * | 2001-07-07 | 2003-01-16 | Beiersdorf Ag | Osmolyte enthaltende kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der gesunden Haut |
DE10133203A1 (de) * | 2001-07-07 | 2003-01-16 | Beiersdorf Ag | Catechine oder Extrakte von grünem Tee enthaltende kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der gesunden Haut |
DE20209676U1 (de) | 2002-06-22 | 2002-09-26 | Stubna, Eduard, 80634 München | Mittel zum Entfernen von Tätowierungen |
DE10243437A1 (de) * | 2002-09-18 | 2004-04-29 | Pm-International Ag | Kosmetische Formulierung |
US8734421B2 (en) | 2003-06-30 | 2014-05-27 | Johnson & Johnson Consumer Companies, Inc. | Methods of treating pores on the skin with electricity |
US7480530B2 (en) | 2003-06-30 | 2009-01-20 | Johnson & Johnson Consumer Companies, Inc. | Device for treatment of barrier membranes |
CA2556967A1 (en) * | 2004-02-23 | 2005-09-09 | Strategic Science & Technologies, Llc | Topical delivery of a nitric oxide donor to improve body and skin appearance |
JP2007530481A (ja) * | 2004-03-24 | 2007-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | エピナスチン及び1又は2以上の追加のミネラル又は1又は2以上の生薬のコンビネーションを含む皮膚疾患の治療用医薬組成物 |
US9226909B2 (en) | 2004-04-19 | 2016-01-05 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
EP1737441A4 (en) | 2004-04-19 | 2009-05-20 | Strategic Science & Technologi | ADVANTAGEOUS EFFECTS OF REINFORCING LOCAL FLOW |
AT501221A1 (de) * | 2005-01-14 | 2006-07-15 | Hermine Dr Engl | Wirkstoffmischung |
KR101402637B1 (ko) | 2006-03-22 | 2014-06-03 | 다카사고 고료 고교 가부시키가이샤 | 소취제 조성물 |
AU2013203151B2 (en) * | 2007-04-09 | 2015-05-21 | Wake Forest University Health Sciences | Oxygen-generating compositions for enhancing cell and tissue survival in vivo |
US10493040B2 (en) | 2007-04-09 | 2019-12-03 | Wake Forest University Health Sciences | Oxygen-generating compositions for enhancing cell and tissue survival in vivo |
FR2916351B1 (fr) * | 2007-05-22 | 2012-12-07 | Galderma Res & Dev | Composition pharmaceutique comprenant au moins deux composes choisis parmi l'acide pyrrolidone-5-carboxylique, la citrulline, l'arginine et l'asparagine et leur utilisation dans le traitement de la dermatite atopique |
JP5537046B2 (ja) * | 2009-02-20 | 2014-07-02 | 花王株式会社 | ボディーリンス剤 |
US20120089232A1 (en) | 2009-03-27 | 2012-04-12 | Jennifer Hagyoung Kang Choi | Medical devices with galvanic particulates |
US11684624B2 (en) | 2009-06-24 | 2023-06-27 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
EP2445493A1 (en) | 2009-06-24 | 2012-05-02 | Strategic Science & Technologies, LLC | Topical composition containing naproxen |
NZ597542A (en) | 2009-06-24 | 2014-01-31 | Strategic Science & Tech Llc | Topical composition containing ibuprofen |
KR20120091335A (ko) | 2009-11-13 | 2012-08-17 | 존슨 앤드 존슨 컨수머 캄파니즈, 인코포레이티드 | 갈바닉 피부 치료 장치 |
EP3721893A1 (en) | 2010-12-29 | 2020-10-14 | Strategic Science & Technologies, LLC | Treatment of erectile dysfunction |
US9289495B2 (en) | 2010-12-29 | 2016-03-22 | Strategic Science & Technologies, Llc | Systems and methods for treatment of allergies and other indications |
CN102688483B (zh) * | 2011-03-22 | 2015-02-18 | 王成德 | 一种治疗皮肤病的组合物、含有该组合物的制剂及其制备方法 |
RU2457778C1 (ru) * | 2011-05-11 | 2012-08-10 | Государственное бюджетное образовательное учреждение дополнительного профессионального образования "Новокузнецкий государственный институт усовершенствования врачей" Министерства здравоохранения и социального развития Российской Федерации | Способ диагностики нарушения микроциркуляции тонкой кишки у пациентов с разлитым перитонитом |
DE102011109868A1 (de) * | 2011-08-10 | 2013-02-14 | STERNA BIOLOGICALS GmbH & Co. KG. | Multiple Emulsion |
WO2014041528A2 (en) * | 2012-09-14 | 2014-03-20 | Martin Roslain Margaret | A composition |
AU2013367193A1 (en) | 2012-12-26 | 2015-07-16 | A-Z Ltd. | Wound healing accelerator |
CN104173232A (zh) * | 2014-08-06 | 2014-12-03 | 金玲 | 一种提升肌肤抵抗力并修复微损肌肤的美容液制作方法 |
CN104189000A (zh) * | 2014-09-12 | 2014-12-10 | 朴荣范 | 外伤药液及其制备方法 |
WO2016128235A1 (en) * | 2015-02-11 | 2016-08-18 | Nestec S.A. | Vitamin a composition |
CN105901703B (zh) * | 2016-04-19 | 2020-03-10 | 上海海洋大学 | 一种用于烧伤患者的海洋生物型肠内营养制剂 |
EA038885B1 (ru) | 2016-12-21 | 2021-11-02 | ЮНИЛЕВЕР АйПи ХОЛДИНГС Б.В. | Осветляющая кожу добавка для местного применения и композиция с аминокислотами и никотинамидными соединениями |
CA3047215A1 (en) | 2016-12-21 | 2018-06-28 | Unilever Plc | Personal care compositions with cystine |
EP3558243B1 (en) | 2016-12-21 | 2022-10-05 | Unilever IP Holdings B.V. | Personal care compositions comprising poorly soluble compounds |
US11260005B2 (en) | 2016-12-21 | 2022-03-01 | Conopco, Inc. | Personal care compositions with glutathione precursor comprising 4-substituted resorcinols and amino acids |
JP7497296B2 (ja) | 2018-05-23 | 2024-06-10 | ユニリーバー・アイピー・ホールディングス・ベスローテン・ヴェンノーツハップ | ナノエマルジョン及びその製造方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3861868A (en) * | 1971-03-30 | 1975-01-21 | Procter & Gamble | Dyeing human hair with oxidation dyes and arginine or a protamine protein |
DE2840498C2 (de) * | 1978-09-18 | 1980-04-10 | Walter Dr. 6700 Ludwigshafen Schweckendiek | Pharmazeutische Zubereitungen zur Behandlung von Psoriasis |
US4283386A (en) * | 1978-10-10 | 1981-08-11 | Scott Eugene J Van | Method for hair care |
NZ223558A (en) * | 1987-02-18 | 1990-04-26 | Milor Scient Ltd | Acne treatment composition |
DE3905299C1 (zh) * | 1989-02-21 | 1990-08-09 | Peter Prof. Dr.Med. 7980 Ravensburg De Klein | |
FR2651125B1 (fr) * | 1989-08-23 | 1992-10-02 | Roussel Uclaf | Compositions pharmaceutiques de type "pates a l'eau". |
DE69124223T2 (de) * | 1990-02-05 | 1997-04-30 | Lifescience Corp | Vitamine und mineralien enthaltende nahrungszusätze |
FR2674755B1 (fr) * | 1991-04-05 | 1995-02-03 | Thorel Jean Noel | Nouvelles compositions medicamenteuses immunostimulatrices. |
US5681852A (en) * | 1993-11-12 | 1997-10-28 | The Procter & Gamble Company | Desquamation compositions |
FR2727014A1 (fr) * | 1994-11-18 | 1996-05-24 | Rocher Yves Biolog Vegetale | Composition cosmetique et procede pour lutter contre les odeurs corporelles desagreables produites par la transpiration |
US5733535A (en) * | 1995-10-25 | 1998-03-31 | The Procter & Gamble Co. | Topical compositions containing N-acetylcysteine and odor masking materials |
US5597585A (en) * | 1995-12-26 | 1997-01-28 | Williams; Andrew H. | Vitamin/mineral composition |
DE19622708A1 (de) * | 1996-06-05 | 1997-12-11 | Tomic Dobrivoje | Phytobiologische Zubereitungen |
AU3502197A (en) * | 1996-06-27 | 1998-04-02 | Procter & Gamble Company, The | Cosmetic compositions |
-
1998
- 1998-07-15 DE DE19831798A patent/DE19831798A1/de not_active Withdrawn
-
1999
- 1999-07-15 HU HU0103236A patent/HUP0103236A2/hu unknown
- 1999-07-15 CN CNB998098426A patent/CN1201723C/zh not_active Expired - Fee Related
- 1999-07-15 DK DK99947221T patent/DK1096918T3/da active
- 1999-07-15 EP EP05024131A patent/EP1639991A3/de not_active Withdrawn
- 1999-07-15 JP JP2000559824A patent/JP3917370B2/ja not_active Expired - Fee Related
- 1999-07-15 PL PL99345689A patent/PL345689A1/xx not_active Application Discontinuation
- 1999-07-15 KR KR1020017000629A patent/KR100542606B1/ko not_active IP Right Cessation
- 1999-07-15 DE DE59912774T patent/DE59912774D1/de not_active Expired - Fee Related
- 1999-07-15 AT AT99947221T patent/ATE308968T1/de not_active IP Right Cessation
- 1999-07-15 CA CA002337772A patent/CA2337772C/en not_active Expired - Fee Related
- 1999-07-15 DE DE19981295T patent/DE19981295D2/de not_active Expired - Lifetime
- 1999-07-15 BR BR9912821-7A patent/BR9912821A/pt not_active IP Right Cessation
- 1999-07-15 EP EP99947221A patent/EP1096918B1/de not_active Expired - Lifetime
- 1999-07-15 AU AU60778/99A patent/AU761947B2/en not_active Ceased
- 1999-07-15 ES ES99947221T patent/ES2252976T3/es not_active Expired - Lifetime
- 1999-07-15 IL IL14088999A patent/IL140889A0/xx unknown
- 1999-07-15 WO PCT/DE1999/002202 patent/WO2000003689A2/de active IP Right Grant
-
2001
- 2001-01-12 NO NO20010220A patent/NO20010220L/no unknown
- 2001-02-14 ZA ZA200101244A patent/ZA200101244B/xx unknown
- 2001-11-09 HK HK01107891A patent/HK1037958A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HK1037958A1 (en) | 2002-03-01 |
CA2337772A1 (en) | 2000-01-27 |
NO20010220L (no) | 2001-03-13 |
AU761947B2 (en) | 2003-06-12 |
DE59912774D1 (de) | 2005-12-15 |
JP3917370B2 (ja) | 2007-05-23 |
CN1313753A (zh) | 2001-09-19 |
DK1096918T3 (da) | 2006-01-09 |
IL140889A0 (en) | 2002-02-10 |
BR9912821A (pt) | 2001-05-02 |
DE19981295D2 (de) | 2001-08-30 |
WO2000003689A2 (de) | 2000-01-27 |
ES2252976T3 (es) | 2006-05-16 |
JP2002520348A (ja) | 2002-07-09 |
AU6077899A (en) | 2000-02-07 |
EP1639991A3 (de) | 2007-09-05 |
KR100542606B1 (ko) | 2006-01-11 |
ZA200101244B (en) | 2003-05-14 |
CA2337772C (en) | 2009-06-09 |
DE19831798A1 (de) | 2000-01-27 |
WO2000003689A3 (de) | 2000-04-20 |
EP1639991A2 (de) | 2006-03-29 |
HUP0103236A2 (hu) | 2002-02-28 |
NO20010220D0 (no) | 2001-01-12 |
EP1096918A2 (de) | 2001-05-09 |
EP1096918B1 (de) | 2005-11-09 |
KR20010070965A (ko) | 2001-07-28 |
ATE308968T1 (de) | 2005-11-15 |
PL345689A1 (en) | 2002-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1201723C (zh) | 皮肤与组织护理和/或治疗制剂及其应用 | |
CA1125172A (fr) | Composition medicamenteuse et procede de preparation | |
JP2002520348A5 (zh) | ||
KR101702851B1 (ko) | 발모촉진, 탈모예방과 모낭개선용 식용귀뚜라미 조성물 | |
CN108452275A (zh) | 一种具有舒筋活络功效的组合物、药剂及制备方法 | |
CN109287828A (zh) | 一种番茄酵母压片糖果及其制备工艺 | |
WO2015010371A1 (zh) | 一种用于治疗青春痘色素沉斑和美白的精华液 | |
US20080152733A1 (en) | Noni juice composition | |
US20090208593A1 (en) | Phyto aroma micro-nutritherapeutic compositions in orodietology | |
CN109602645B (zh) | 一种减肥复方精油及其制备方法 | |
KR20110121246A (ko) | 비만개선 다이어트용 웰빙 한방식품 및 그 제조방법 | |
KR101163069B1 (ko) | 주름 및 잡티 개선용 화장료 조성물 및 이의 제조방법 | |
CN107281084A (zh) | 一种美白中药面膜及其制备方法 | |
JPS59137405A (ja) | 化粧料 | |
US20040146587A1 (en) | Topical composition for relief of pain and minor skin irritations | |
CN110051723A (zh) | 一种沙棘果口腔喷雾及其制备方法 | |
RU2419446C1 (ru) | Состав экстракта хвои густого для капсулирования | |
KR20050080501A (ko) | 고혈압, 비만, 당뇨병환자를 위한 건강보조식품의 제조방법 | |
CN109316552A (zh) | 一种治疗足癣的药物组合物 | |
Molayem | Current evidence on the use of curcumin in modern periodontology-A narrative review | |
CA2745579A1 (en) | Thick pine needle extract composition for capsulation | |
KR101312257B1 (ko) | 수용성 진주분말을 포함하는 잇몸도포제 | |
JP6943941B2 (ja) | レモンバーム抽出物を有効成分として含む注射剤及び化粧料組成物 | |
CN101053548A (zh) | 修复霜 | |
CN107375165A (zh) | 一种具有美容效果的组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050518 Termination date: 20100715 |